Aclaris Therapeutics Inc (ACRS)

Apr 02, 2025

Charles Schwab Investment Management Inc. Makes New Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Apr 02, 2025

Apr 01, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest - Defense World

Apr 01, 2025

Apr 01, 2025

Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $11.67 - Defense World

Apr 01, 2025

Mar 31, 2025

Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely? - Yahoo Finance

Mar 31, 2025

Mar 29, 2025

HighTower Advisors LLC Has $652,000 Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Mar 29, 2025

Mar 27, 2025

Aclaris at H.C. Wainwright Conference: Strategic Moves in Immuno-Inflammatory Diseases - Investing.com India

Mar 27, 2025

Mar 23, 2025

Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN

Mar 23, 2025

Mar 22, 2025

Cantor Fitzgerald Has Weak Forecast for ACRS FY2025 Earnings - The AM Reporter

Mar 22, 2025

Mar 21, 2025

Aclaris Therapeutics ATM - Leerink Partners

Mar 21, 2025

Mar 19, 2025

Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald - Yahoo Finance

Mar 19, 2025

Mar 19, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Now Covered by Analysts at Cantor Fitzgerald - Defense World

Mar 19, 2025

Mar 12, 2025

Aclaris Reports 2024 Financial Results and Sets Stage for Transformative 2025 - MSN

Mar 12, 2025

Mar 12, 2025

Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 11, 2025

Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion - Investing.com

Mar 11, 2025

Mar 11, 2025

Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MSN

Mar 11, 2025

Mar 11, 2025

Common Warts Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail

Mar 11, 2025

Mar 09, 2025

Scotiabank Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World

Mar 09, 2025

Mar 08, 2025

Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025

Mar 08, 2025

Scotiabank Initiates Coverage of Aclaris Therapeutics (ACRS) with Sector Outperform Recommendation - Nasdaq

Mar 08, 2025

Mar 07, 2025

Scotiabank sets Aclaris stock target at $15 with new rating - Investing.com

Mar 07, 2025

Mar 07, 2025

Scotiabank sets Aclaris stock target at $15 with new rating By Investing.com - Investing.com UK

Mar 07, 2025

Mar 07, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - Simply Wall St

Mar 07, 2025

Mar 07, 2025

Cantor Fitzgerald Predicts ACRS FY2025 Earnings - Defense World

Mar 07, 2025

Mar 07, 2025

Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $11.00 - Defense World

Mar 07, 2025

Mar 06, 2025

Aclaris Therapeutics (NASDAQ:ACRS shareholders incur further losses as stock declines 12% this week, taking three-year losses to 88% - Simply Wall St

Mar 06, 2025

Mar 06, 2025

Cantor Fitzgerald Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to Strong-Buy - Defense World

Mar 06, 2025

Mar 05, 2025

Aclaris Therapeutics plans $300M mixed shelf offering - MSN

Mar 05, 2025

Mar 04, 2025

Aclaris Therapeutics to Participate in Two March Healthcare Conferences - GlobeNewswire

Mar 04, 2025

Mar 04, 2025

Will Aclaris Therapeutics Reveal New Pipeline Updates at March Healthcare Conferences? - StockTitan

Mar 04, 2025

Mar 04, 2025

This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year - Yahoo Finance

Mar 04, 2025

Mar 03, 2025

JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.

Mar 03, 2025

Mar 03, 2025

Aclaris Therapeutics Inc (NASDAQ: ACRS): Hidden Gems In A Time Of Volatility - Stocks Register

Mar 03, 2025

Mar 03, 2025

Hair Loss Treatment Market Hits New High | Major Giants Follica, Theradome, Histogen, Aclaris Therapeutics - Newstrail

Mar 03, 2025

Mar 03, 2025

Q1 Earnings Forecast for ACRS Issued By Leerink Partnrs - Defense World

Mar 03, 2025

Feb 28, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results - MarketBeat

Feb 28, 2025

Feb 28, 2025

Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Feb 28, 2025

Feb 27, 2025

Aclaris Therapeutics Reports 2024 Financial Results - TipRanks

Feb 27, 2025

Feb 27, 2025

Aclaris: Q4 Earnings Snapshot - CT Insider

Feb 27, 2025

Feb 27, 2025

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates - MSN

Feb 27, 2025

Feb 27, 2025

Aclaris Therapeutics Inc earnings missed by $0.72, revenue topped estimates - Investing.com

Feb 27, 2025

Feb 27, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat

Feb 27, 2025

Feb 27, 2025

Aclaris Therapeutics reports Q4 EPS ($1.01), consensus (38c) - TipRanks

Feb 27, 2025

Feb 27, 2025

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times

Feb 27, 2025